Madrigal Pharmaceuticals

Overview

Madrigal Pharmaceuticals is a biopharmaceutical company based in Pennsylvania, founded in 2016 by CMO Rebecca Taub. The company specializes in developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can lead to severe complications such as cirrhosis and liver cancer.

Madrigal has achieved the first U.S. FDA-approved treatment for MASH, focusing on halting or reversing liver fibrosis. The company conducts extensive research and clinical trials to advance therapies targeting the pathology of MASH. Its R&D strategy includes both early safety studies and large-scale Phase 3 clinical trials, emphasizing the development of therapeutics that aim to improve clinical outcomes for patients suffering from this condition.

Basic Information

Contact Details

• Phone: +1 610-937-1951
• Website: madrigalpharma.com
• LinkedIn: linkedin.com/company/madrigal-pharmaceuticals-inc-

Key Focus Areas & Initiatives

• Liver disease research
• Development of novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH)
• FDA-approved treatment for MASH
• Halting or reversing liver fibrosis progression
• Phase 3 clinical trials and research programs
• Therapeutic approaches for cirrhosis and liver cancer
• Improving clinical outcomes for patients

Technologies Used

• Cloudflare DNS
• Drupal
• Microsoft Office 365
• Mimecast

Affiliated Organizations & Regional Branches

• Madrigal Pharmaceuticals, Inc.